Stay updated with breaking news from Pardes Bioscience. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
CARLSBAD, Calif., Aug. 15, 2022 -- Pardes Biosciences, Inc. , a clinical-stage biopharmaceutical company developing PBI-0451 as a potential novel oral antiviral drug candidate for the treatment and... | August 15, 2022
Equities research analysts predict that Pardes Biosciences, Inc. (NASDAQ:PRDS – Get Rating) will announce earnings of ($0.39) per share for the current fiscal quarter, according to Zacks. Zero analysts have issued estimates for Pardes Biosciences’ earnings, with the lowest EPS estimate coming in at ($0.40) and the highest estimate coming in at ($0.38). The company […]
Wall Street analysts predict that Pardes Biosciences, Inc. (NASDAQ:PRDS – Get Rating) will post earnings per share of ($0.25) for the current quarter, Zacks reports. Zero analysts have made estimates for Pardes Biosciences’ earnings. The highest EPS estimate is ($0.23) and the lowest is ($0.27). The company is expected to issue its next earnings report […]
Read the latest stock market news on MarketBeat. Get real-time analyst ratings, dividend information, earnings results, financials, headlines, insider trades and options data for any stock.
Pardes Biosciences Inc (NASDAQ:PRDS – Get Rating) – Equities researchers at SVB Leerink lowered their FY2023 EPS estimates for Pardes Biosciences in a report issued on Wednesday, March 30th. SVB Leerink analyst R. Ruiz now anticipates that the company will post earnings per share of $7.00 for the year, down from their prior estimate of […]